Evidence map›Paper›PMID 41859417›Full record

ReviewFrontiers in neurology2026

Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Pietro Annovazzi, Marinella Clerico, Eleonora Cocco, Antonella Conte, Girolama Alessandra Marfia, Marco Salvetti, Valentina Tomassini, Rocco Totaro, Diego Centonze

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Pietro AnnovazziNeuroimmunology Unit, ASST Valle Olona, Gallarate Hospital, Gallarate, VA, Italy.
Marinella ClericoClinical and Biological Sciences Department, University of Torino, Torino, Italy.
Eleonora CoccoMedical Sciences and Public Health Department, University of Cagliari, Cagliari, Italy.
Antonella ConteDepartment of Human Neurosciences, Sapienza University, Rome, Italy.
Girolama Alessandra MarfiaDepartment of Systems Medicine, Tor Vergata University, Rome, Italy.
Marco SalvettiUnit of Neurology, IRCCS Neuromed, Pozzilli, IS, Italy.
Valentina TomassiniDepartment of Neurosciences, Imaging and Clinical Sciences, University G. D'Annunzio, Chieti-Pescara, Italy.
Rocco TotaroDemyelinating Disease Center Department of Neurology, San Salvatore Hospital, L'Aquila, Italy.
Diego CentonzeUnit of Neurology, IRCCS Neuromed, Pozzilli, IS, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent introduction of High-Efficacy Therapies (HETs) in clinical practice has drastically reduced the frequency of acute inflammatory episodes and relapses, in patients with Multiple Sclerosis (MS), gradually shifting the interest of clinicians toward preventing disease progression and treating symptoms associated with the residual disease. This article summarizes the output of a recent meeting (June 2025, in Rome) among an Italian group of neurologists, who discussed about published evidence supporting the involvement of the endocannabinoid system (ECS) in MS spasticity and its associated symptoms. Sharing their clinical experiences about the silent progression of the disease, in patients with Relapse-Free Multiple Sclerosis (RFMS), treated with HETs, authors propose a new algorithm to treat residual disease in RFMS, by enhancing ECS with both cannabinoid agents and lifestyle interventions (diet and physical activity).

Indexed as

algorithms of treatmentlifestyle interventionsnabiximolsSmouldering Diseasespasticity-plus-syndrome

Identifiers

PMID41859417
PMCPMC12997178

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.